Literature DB >> 14647260

Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease.

S Imashuku, T Teramura, A Morimoto, M Naya, H Kuroda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14647260     DOI： 10.1038/sj.bmt.1704307

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

1.  Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.

Authors:  Nicolò Compagno; Francesco Cinetto; Gianpietro Semenzato; Carlo Agostini
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

2.  Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis.

Authors:  Erika Irie; Yuko Shirota; Chihiro Suzuki; Yumi Tajima; Kenichi Ishizawa; Junichi Kameoka; Hideo Harigae; Tomonori Ishii
Journal:  Int J Hematol       Date:  2010-03-10       Impact factor: 2.490

3.  B cell depletion for autoimmune diseases in paediatric patients.

Authors:  Annette F Jansson; Claudia Sengler; Jasmin Kuemmerle-Deschner; Bernd Gruhn; A Birgitta Kranz; Hartwig Lehmann; Daniela Kleinert; Lars Pape; Hermann J Girschick; Ivan Foeldvari; Dieter Haffner; Johannes P Haas; Dagmar Moebius; Dirk Foell; Joachim Peitz; Veit Grote
Journal:  Clin Rheumatol       Date:  2010-12-01       Impact factor: 2.980

4.  Targeting lentiviral vectors to antigen-specific immunoglobulins.

Authors:  Leslie Ziegler; Lili Yang; Kye il Joo; Haiguang Yang; David Baltimore; Pin Wang
Journal:  Hum Gene Ther       Date:  2008-09       Impact factor: 5.695

Review 5.  Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.

Authors:  Vidhya Murukesan; Sandeep Mukherjee
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

6.  Central nervous system involvement of epstein barr virus associated lymphoproliferative disorder in a child with acute lymphoblastic leukemia: successful treatment with rituximab and interferon-alpha.

Authors:  Berna Atabay; Meral Türker; Can Oztürk; Sümer Sütçüoğlu; Haldun Oniz; Esra Arun Ozer
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

Review 7.  Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?

Authors:  Jennifer Worch; Olga Makarova; Birgit Burkhardt
Journal:  Cancers (Basel)       Date:  2015-01-29       Impact factor: 6.639

Review 8.  Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.

Authors:  Nicolò Compagno; Giacomo Malipiero; Francesco Cinetto; Carlo Agostini
Journal:  Front Immunol       Date:  2014-12-08       Impact factor: 7.561

9.  Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT.

Authors:  Fanny Luterbacher; Fanette Bernard; Frédéric Baleydier; Emmanuelle Ranza; Peter Jandus; Geraldine Blanchard-Rohner
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.